» Articles » PMID: 17005662

Induction of Robust Immune Responses Against Human Immunodeficiency Virus is Supported by the Inherent Tropism of Adeno-associated Virus Type 5 for Dendritic Cells

Overview
Journal J Virol
Date 2006 Sep 29
PMID 17005662
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

The ability of adeno-associated virus serotype 1 to 8 (AAV1 to AAV8) vectors expressing the human immunodeficiency virus type 1 (HIV-1) Env gp160 (AAV-HIV) to induce an immune response was evaluated in BALB/c mice. The AAV5 vector showed a higher tropism for both mouse and human dendritic cells (DCs) than did the AAV2 vector, whereas other AAV serotype vectors transduced DCs only poorly. AAV1, AAV5, AAV7, and AAV8 were more highly expressed in muscle cells than AAV2. An immunogenicity study of AAV serotypes indicates that AAV1, AAV5, AAV7, and AAV8 vectors expressing the Env gp160 gene induced higher HIV-specific humoral and cell-mediated immune responses than the AAV2 vector did, with the AAV5 vector producing the best responses. Furthermore, mice injected with DCs that had been transduced ex vivo with an AAV5 vector expressing the gp160 gene elicited higher HIV-specific cell-mediated immune responses than did DCs transduced with AAV1 and AAV2 vectors. We also found that AAV vectors produced by HEK293 cells and insect cells elicit similar levels of antigen-specific immune responses. These results demonstrate that the immunogenicity of AAV vectors depends on their tropism for both antigen-presenting cells (such as DCs) and non-antigen-presenting cells (such as muscular cells) and that AAV5 is a better vector than other AAV serotypes. These results may aid in the development of AAV-based vaccine and gene therapy.

Citing Articles

A two-dose viral-vectored multistage vaccine confers durable protection and transmission-blockade in a pre-clinical study.

Yamamoto Y, Fabbri C, Okuhara D, Takagi R, Kawabata Y, Katayama T Front Immunol. 2024; 15:1372584.

PMID: 38745665 PMC: 11091281. DOI: 10.3389/fimmu.2024.1372584.


Correlating physicochemical and biological properties to define critical quality attributes of a rAAV vaccine candidate.

Kumar P, Wang M, Kumru O, Hickey J, Sanmiguel J, Zabaleta N Mol Ther Methods Clin Dev. 2023; 30:103-121.

PMID: 37746246 PMC: 10512015. DOI: 10.1016/j.omtm.2023.06.004.


Transcriptomic Analysis Reveals the Inability of Recombinant AAV8 to Activate Human Monocyte-Derived Dendritic Cells.

Masri S, Carre L, Jaulin N, Vandamme C, Couzinie C, Guy-Duche A Int J Mol Sci. 2023; 24(13).

PMID: 37445621 PMC: 10341499. DOI: 10.3390/ijms241310447.


Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer.

Arjomandnejad M, Dasgupta I, Flotte T, Keeler A BioDrugs. 2023; 37(3):311-329.

PMID: 36862289 PMC: 9979149. DOI: 10.1007/s40259-023-00585-7.


Immune profiling of adeno-associated virus response identifies B cell-specific targets that enable vector re-administration in mice.

Chen M, Kim B, Jarvis M, Fleury S, Deng S, Nouraein S Gene Ther. 2022; 30(5):429-442.

PMID: 36372846 PMC: 10183056. DOI: 10.1038/s41434-022-00371-0.


References
1.
Moore M, McGarvey M, Russell R, Cullen B, McClure M . Stable inhibition of hepatitis B virus proteins by small interfering RNA expressed from viral vectors. J Gene Med. 2005; 7(7):918-25. DOI: 10.1002/jgm.739. View

2.
Tomar R, Matta H, Chaudhary P . Use of adeno-associated viral vector for delivery of small interfering RNA. Oncogene. 2003; 22(36):5712-5. DOI: 10.1038/sj.onc.1206733. View

3.
Rutledge E, Halbert C, Russell D . Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J Virol. 1998; 72(1):309-19. PMC: 109378. DOI: 10.1128/JVI.72.1.309-319.1998. View

4.
Meghrous J, Aucoin M, Jacob D, Chahal P, Arcand N, Kamen A . Production of recombinant adeno-associated viral vectors using a baculovirus/insect cell suspension culture system: from shake flasks to a 20-L bioreactor. Biotechnol Prog. 2005; 21(1):154-60. DOI: 10.1021/bp049802e. View

5.
Chiriva-Internati M, Liu Y, Salati E, Zhou W, Wang Z, Grizzi F . Efficient generation of cytotoxic T lymphocytes against cervical cancer cells by adeno-associated virus/human papillomavirus type 16 E7 antigen gene transduction into dendritic cells. Eur J Immunol. 2001; 32(1):30-8. DOI: 10.1002/1521-4141(200201)32:1<30::AID-IMMU30>3.0.CO;2-E. View